Yes. Clinical trials consistently show that 25–40% of weight lost on GLP-1 therapy comes from lean muscle mass, not fat. In the landmark STEP 1 semaglutide trial, the average lean mass lost was 6.92 kg per patient — representing 40% of total weight lost. This is not a direct side effect of the drug itself, but the predictable result of appetite suppression reducing protein intake below what muscle maintenance requires.

Not necessarily. The composition of the weight lost matters as much as the amount. If a significant proportion comes from lean muscle mass rather than fat, the metabolic consequences can undermine long-term health: a lower resting metabolic rate increases the risk of weight regain, and reduced muscle mass is independently associated with higher rates of insulin resistance, cardiovascular risk, and functional decline. Weight loss with preserved or improved lean mass produces meaningfully better long-term outcomes.

Clinically, yes. Lean mass loss at the rate documented in GLP-1 trials compresses years of normal age-related muscle decline into months of treatment. This reduces metabolic rate, impairs insulin sensitivity, reduces the body’s reserve for immune function and recovery from illness, and creates the biological conditions for weight regain after treatment ends. For adults over 45, perimenopausal women, and those with type 2 diabetes — the populations most commonly prescribed GLP-1 therapy — the risk is particularly significant.

Yes. Skeletal muscle is metabolically expensive tissue — it burns energy continuously, at rest, during sleep, and throughout daily activity. It is the primary driver of resting metabolic rate. When lean mass declines, resting metabolic rate falls proportionally. Research shows that muscle loss reduces basal metabolic rate by 5–10%. Over time, this creates a persistent caloric imbalance that makes weight maintenance progressively more difficult — independent of diet or willpower.

A frequently recommended clinical target is 1.2–1.6 g of protein per kg of body weight per day — rising to 1.6–2.2 g/kg on days that include resistance training. For a 90 kg adult, that means at least 108–144 g of protein per day. On effective GLP-1 therapy, where appetite is significantly suppressed, this is rarely achievable through food alone. FORZET™ is designed specifically to bridge this gap, delivering essential amino acids without requiring additional food volume.

The body does not need protein as such, but the Essential Amino Acids contained in protein. A minimum of 55% of the protein is non-essential amino acids that the body does not need. Any non-essential amino acids that the body does not need will be excreted, placing burden on the kidneys which should be avoided in persons with decreased kidney function, a frequent condition in persons with obesity or overweight.

Yes. When GLP-1 therapy ends and weight is regained, it returns predominantly as adipose tissue rather than lean mass. Clinical extension data from STEP 1 show a mean weight regain of 9.69 kg within one year of stopping semaglutide — mostly fat. This compositional asymmetry occurs because fat accumulates readily with any caloric surplus, while rebuilding muscle requires adequate protein, progressive mechanical load, and time. A patient who lost significant lean mass during treatment may end up lighter but with proportionally more fat and a lower resting metabolic rate than before they started.

No. One of the most clinically significant aspects of GLP-1 therapy is that its appetite-suppressing effects reverse rapidly after discontinuation — typically within weeks. Appetite returns into a body with a lower resting metabolic rate (if lean mass was lost), making weight regain nearly inevitable without the nutritional and exercise habits established during treatment. This is why the protocol established on FORZET™ — adequate EAA intake, resistance training, body composition monitoring — must continue beyond the treatment period, not just during it.

Body weight is a single number that tells you nothing about what it is composed of. Two patients can lose the same 12 kg on GLP-1 therapy: one loses 10 kg of fat and 2 kg of muscle; the other loses 7 kg of fat and 5 kg of muscle. On the scale, identical. In terms of metabolic rate, insulin sensitivity, and long-term health, profoundly different. Body composition monitoring with BIA (bioelectrical impedance analysis) measures fat mass, lean mass, body water, and visceral fat separately — giving you the information the scale cannot.

‘Ozempic face’ describes the facial volume loss and skin laxity that some patients experience during rapid GLP-1-induced weight loss. It is not a pharmacological side effect — GLP-1 does not selectively deplete facial fat. Rather, fat is lost from the face as from everywhere else. When that loss is rapid, the skin — which may have lost elasticity with age or from the rate of change — does not immediately adapt to the new facial contours. It typically becomes noticeable between 3 and 6 months into treatment and is more pronounced in adults over 45. ZKINFIRM™, combined with adequate EAA intake through FORZET™, supports both collagen precursor availability and topical skin health from Day 1.

Nutrition always comes first. This is not a preference — it is a clinical necessity. When structured exercise is initiated before adequate protein and EAA intake is established, the body’s amino acid demand from exercise increases without the supply to meet it. The result is that the body catabolises existing muscle to compensate, accelerating the very loss exercise is meant to prevent. The IOC’s RED-S framework documents precisely this risk. Establish FORZET™ and meet protein targets first. Add resistance training after 2–4 weeks of nutritional stability.

No. Muscle protein synthesis cannot proceed without all nine essential amino acids present simultaneously. EAAs cannot be made by the body — they must come from diet. Leucine, specifically, is the molecular trigger for the mTORC1 pathway that initiates the muscle-building process. Without adequate leucine (approximately 2.5–3 g per meal), the anabolic response is significantly blunted regardless of total protein consumed. FORZET™ delivers all nine EAAs in free-form — directly absorbed, bypassing the digestive constraints that food protein faces.

For most adults on GLP-1 therapy, yes. When total food volume is significantly reduced by appetite suppression, protein intake falls below the threshold muscle protein synthesis requires. This deficit is not visible on the scale and not felt as hunger — it accumulates silently. Free-form EAA supplementation with FORZET™ bridges this gap precisely and efficiently, without adding food volume, caloric load, or digestive demand. It is not supplementation for its own sake — it is targeted nutritional support for a specific and clinically documented deficit.

Day 1 of GLP-1 therapy. The most effective time to protect lean mass is before it begins to decline. Once muscle is lost, rebuilding it requires the same nutritional conditions plus progressive mechanical load — and takes significantly longer than prevention. If you are already mid-treatment, the right time to start is now. Every week of GLP-1 therapy without EAA support represents lean mass at risk.

Throughout your GLP-1 therapy and post-discontinuation while building muscle for maintaining weight loss.

The yo-yo effect is the pattern of weight regain after successful weight loss — predominantly fat, not muscle. It occurs because lean mass lost during treatment reduces resting metabolic rate, meaning the caloric intake that was previously weight-neutral now generates a surplus stored as fat. Patients who preserve lean mass during GLP-1 therapy have a protected metabolic rate when treatment ends and are far less biologically set up for regain. FORZET™ provides the nutritional foundation that makes lean mass preservation possible throughout treatment.

Professional BIA (bioelectrical impedance analysis) is a body composition scan that measures fat mass, lean mass, body water, and visceral fat in under one minute. It is the only way to know whether your GLP-1 strategy is actually protecting your muscle. A baseline scan before or at the start of therapy is strongly recommended. Use forzet.me/analysis to find a clinic near you. We will not have it at the beginning when the Flowcode goes live.

ZKINFIRM™ is the skin-support component of our GLP-1 optimization protocol — a clinically formulated topical product for the skin changes associated with rapid GLP-1 weight loss, including ‘Ozempic face’, elasticity loss, and hair shedding.